ENVALITH

RaQualia Pharma Inc. 3Q Earnings Call Flash

JPY 200M Upfront Payment from Hisamitsu to Be Booked in 4Q; Brazil Approval Further Expands Tegoprazan Footprint; Focus Shifts to Out-Licensing Progress

PublishedNovember 17, 2026 at 22:15 GMT+9

Summary

Cumulative 3Q royalties ran at a record pace. However, lower other revenue limited operating revenue growth to a marginal increase, and losses narrowed at every profit level. At the briefing, management said verbally that a JPY 200M upfront payment from Hisamitsu Pharmaceutical will be booked in 4Q. It also announced tegoprazan's marketing approval in Brazil, which was disclosed on the day of the call. The expected US approval timing of January 2027 remains unchanged. Management acknowledged, however, that out-licensing deals planned for 2026 are running behind initial expectations. Whether the full-year guidance is achieved will depend on how much other revenue is booked in 4Q.

Key Points (Earnings Highlights and Growth Actions)

  • Management Strategy and Market Perception
    • Management frames corporate value in three tiers. Tier 1 is royalties from marketed products, Tier 2 is out-licensed assets, and Tier 3 is the drug discovery platform. The aim is to make results more visible and counter a market valuation skewed toward short-term earnings
    • The share price is down 31.4% YTD, underperforming both TOPIX and the Growth Market Index. Management attributes this to quarterly swings from upfront and milestone payments, which make earnings look more volatile than the underlying business
    • Management rejected the idea of tolerating losses indefinitely. It will tighten investment discipline, deciding whether to continue, scale back or discontinue research themes even mid-year
    • The global peptic ulcer drug market has traditionally been sized at around JPY 2T. Management believes it is now approaching JPY 3T
  • Current Business Progress and Drivers
    • Standalone 3Q royalties were JPY 827M (our estimate), above the JPY 630M (our estimate) booked in standalone 3Q of the prior year
    • The decline in other revenue reflects a tough comparison, as fewer upfront and milestone payments were booked than in the prior-year period
    • K-CAB ranked first among more than 10,000 drugs by outpatient prescription sales in April. Management positions it as the undisputed No.1
    • In China, the product also leads P-CAB sales, and the injectable formulation is in preparation for Phase III trials
  • Key Strategic Initiatives and Inflection Points
    • The sodium channel blocker out-licensed to Hisamitsu Pharmaceutical has entered Phase II, triggering a JPY 200M upfront payment. It is expected to be booked in 4Q operating revenue
    • Sublicensee Eurofarma obtained marketing approval in Brazil. The approval was announced on the day of the call and is not reflected in the presentation materials
    • Since 2025, the company has launched a joint research program with RIKEN on computational science AI, in addition to its collaboration with HK inno.N
    • Through its capital and business alliance with HK inno.N, the company has moved into exploratory research in metabolic and endocrine diseases

Outlook and Strategy

  • Against the full-year operating revenue plan of JPY 3,980M, 4Q requires JPY 1,630M (our estimate). Management stressed that whether, when and how much other revenue will be booked remains uncertain
  • Management noted that full-year royalties could approach JPY 2.5B if 4Q tracks the same pace. Even assuming this and adding the JPY 200M from Hisamitsu, roughly JPY 985M in other revenue is still required (our estimate)
  • In the US, approval is expected in early 2027, followed by launch, with a meaningful sales ramp anticipated through 2028
  • Management explicitly stated that out-licensing of the ghrelin receptor agonist and the IRAK-M degrader within the year is behind initial expectations. It will prioritize deals that reflect asset value over deal count or deadlines
  • Royalties alone will still not sustain an operating profit in 2027. The target revenue structure combines royalties with upfront and milestone payments
  • Shareholder returns are not premised on indefinite deferral. Decisions will weigh earnings power, cash on hand and share price levels, and partial or phased implementation is also under consideration

Positive Factors

  • In the US TRIUMpH-EE trial, tegoprazan demonstrated superiority over lansoprazole in severe EE. The 2-week complete healing rate was +19.6pt higher, and the 24-week maintenance rate was +32.1pt higher
  • In the US, applications have been filed for three indications: EE healing, maintenance therapy and NERD. Management said there has been no interruption of the FDA review and no negative information has surfaced to date
  • In Korea, the addition of NSAID-induced ulcer prevention brings approved indications to six, the most in its class. This opens room to capture new prevention demand
  • Sales have launched in Paraguay and Ecuador. Approvals have been granted in Uzbekistan and Belarus, and reviews are progressing in South Africa and the Middle East/North Africa
  • Cash on hand stands at JPY 5.4B. Financial flexibility has improved through capital strengthening from the HK inno.N alliance and debt repayment
  • TPD is moving toward commercialization, with the world's first approval granted in May 2026. FIMECS's RaPPIDS platform can synthesize and evaluate over 1,500 degraders per week

Concerns and Risks

  • 4Q other revenue depends on deal closings and partner decisions. One questioner noted that guidance was revised in both 2023 and 2024 after December deal timing slipped into the next period
  • 2026 out-licensing catalysts are delayed, and the stage and likelihood of individual negotiations are undisclosed. This makes progress hard to track from the outside
  • There are reports of other companies obtaining approval in India. Management said the royalty impact of competitive entry cannot be reasonably estimated
  • A shareholder pointed out that no new development candidates or out-licensable assets have emerged since the management change. Management accepts this as an issue to address
  • US approval depends on the FDA and cannot be guaranteed. Any delay would affect the growth scenario for 2027 and beyond

Performance Highlights

Cumulative 3Q operating revenue was JPY 2,350M (+1.7%). This fell short of operating expenses of JPY 2,589M (-2.5%), resulting in an operating loss of JPY 238M versus a loss of JPY 344M in the prior-year period. The recurring loss was JPY 261M, and the quarterly net loss attributable to owners of parent was JPY 493M, with losses narrowing at both levels. EBITDA improved to JPY 102M from JPY 9M in the prior-year period.

Segment Performance

SegmentRevenueYoYOperating IncomeYoY
Consolidated TotalJPY 2,350M+1.7%-JPY 238M―
Royalty RevenueJPY 2,055M+20.6%――
Other Revenue (Upfront Payments, Milestones, Research Collaboration Fees)JPY 295M-51.4%――
  • Progress Toward Full-Year Operating Revenue Plan: 59.1%
  • K-CAB Prescription Sales in Korea (Cumulative 3Q): KRW 185.4B (approx. JPY 20.4B) (+15.3% YoY)
  • K-CAB Share of Korean Acid Suppressant Market: 15% (No.1)
  • Number of Countries Where Tegoprazan Is Marketed: 22
  • Cash and Cash Equivalents: JPY 4,814M (+48.4% vs. prior fiscal year-end)
  • Equity Ratio: 72.2% (+7.1pt vs. prior fiscal year-end)

Q&A List

  • Q

    The +20% growth in royalty revenue is very encouraging. I would like to ask about 4Q other revenue. In both 2023 and 2024, guidance was revised in December because deal timing slipped. Last year, however, guidance was achieved from 3Q progress of 58.1%. This year's progress of 59.1% is roughly in line with last year. To the extent you can share, is the revenue expected in 4Q this year mainly high-certainty items, as last year, or mainly items dependent on negotiation outcomes, as in the previous two years?

    A

    Royalty revenue through 3Q has been tracking well. However, achieving full-year guidance requires booking a certain amount of other revenue in 4Q, such as milestone income and upfront payments. This revenue depends on deal closings, development milestones and decisions by stakeholders, including partners. As noted in the presentation, whether, when and how much will be booked is not yet confirmed and remains uncertain. We trust you understand that maintaining full-year guidance does not guarantee the closing of any specific deal or its revenue recognition. We will refrain from commenting on the details or likelihood of individual deals, given the potential impact on negotiations and confidentiality obligations. Taking into account the nature of other revenue and current progress, we are maintaining full-year consolidated guidance for now. If we judge a revision necessary, we will disclose it promptly.

  • Q

    Among the catalysts expected for 2026, could you share, to the extent possible, the current status of out-licensing the ghrelin receptor agonist?

    A

    We are currently pursuing business development activities to secure a partner.

  • Q

    Could you share, to the extent possible, the current status of out-licensing the IRAK-M degrader?

    A

    As with the ghrelin receptor agonist, we are pursuing business development activities to secure a partner. As mentioned in the main presentation, there has also been progress on the IP front, including the grant of a composition-of-matter patent.

  • Q

    Regarding RaPPIDS, what is the current status of new partnerships beyond Astellas Pharma?

    A

    Our joint research with Astellas Pharma is ongoing. Creating new partnership opportunities is also very important, and we are working on it.

  • Q

    Could you share, to the extent possible, the current status of out-licensing tegoprazan in Europe?

    A

    We do not hold the European rights to tegoprazan directly. We presented this as an anticipated development rather than an action for us this year. It concerns a partner for our licensee HK inno.N, and we are supporting efforts to secure one.

  • Q

    For the four items above, how do you assess progress against this year's targets: on plan, slightly behind or significantly behind? Has the situation improved or worsened since August? Which is progressing best, and which is furthest behind?

    A

    These four items are the cases our group has cited as 2026 catalysts. Progress on any of them would clearly enhance corporate and shareholder value. Frankly, since we have not been able to announce any closings as of November 17, it is a fact that we are behind initial expectations. We aimed to move quickly, so the delay is real. We will refrain from commenting on the negotiation stage of individual deals, comparisons with August or rankings among deals, as this could affect ongoing discussions. What matters is not signing deals that erode asset value for the sake of deal count or deadlines. It is to secure partnerships that properly reflect the value of each asset. That said, having presented them as catalysts, we recognize they have shaped your expectations. We will disclose any progress promptly.

  • Q

    In India, Dr. Reddy's markets tegoprazan, but there are reports that Hetero Labs and Alkem have also obtained approval. How do you view the possibility of companies other than Dr. Reddy's entering the market, and how does this relate to IP and exclusivity agreements?

    A

    In India, Dr. Reddy's, HK inno.N's partner, markets tegoprazan. We are aware that other companies are moving toward launch. However, their approval and launch prospects depend on each company's business decisions, regulatory decisions and IP rights, so we will not comment specifically. We are also not a party to the agreement between HK inno.N and Dr. Reddy's and are not in a position to comment on exclusivity periods or supply terms. We are closely monitoring the IP and competitive environment in India as a key issue. Where action is required of us as rights holder or contracting party, we are responding appropriately in coordination with HK inno.N. However, we will refrain from commenting on individual companies.

  • Q

    How do you assess the impact of competitive entry on Dr. Reddy's sales, your royalty revenue and your earnings outlook?

    A

    The impact of competitive entry depends on timing, pricing, indications and sales infrastructure, among other factors. We cannot reasonably estimate the impact on sales or royalties at this point. Our response is to build value and long-term royalties through broad global expansion, not just in India.

  • Q

    An international patent application for an SHP2 degrader, jointly filed by FIMECS and Astellas Pharma, has been published. Could you explain how this SHP2 degrader relates to the joint research, who holds development and commercialization rights, and whether out-licensing to third parties is possible?

    A

    Thank you for following this so closely. As the patent was jointly filed by FIMECS and Astellas Pharma, we do not deny FIMECS's involvement. However, we will refrain from commenting on the substance of the invention, individual joint research programs, rights or contractual treatment.

  • Q

    What is the current development stage of the SHP2 degrader, and what are the next steps?

    A

    The joint research between FIMECS and Astellas Pharma uses RaPPIDS and targets multiple oncology targets. However, the rights, progress and timelines of individual programs are confidential under the agreement and constitute undisclosed research information. We ask for your understanding that we cannot comment.

  • Q

    Since the management change, there has been no visible output from new research. You also had many agreements with other companies. Could you update us on each?

    A

    We take seriously the criticism that new research results are not sufficiently visible. Research takes time, and joint research involves confidentiality obligations, but we do not believe this alone explains the lack of visible results. Our failure to present new development candidates or out-licensable assets is an issue we must resolve. We do not intend to justify the lack of visible results on the grounds that drug discovery takes time. We have pursued various initiatives since the management change. Since I took office in 2025, we have started joint research with HK inno.N and joint research with RIKEN on computational science AI. Internally, we are also working to strengthen Tier 3. We may not be able to disclose individual details or progress. What matters is not signing contracts or launching partnerships per se, but generating results from them, such as development candidates, IP and licensing.

  • Q

    If results have not materialized, what went wrong, and how are those failures being put to use?

    A

    Some technologies do take several years. More often, though, projects cannot advance because the hypothesis is not supported, competitive advantage cannot be established, value to potential customers cannot be sufficiently demonstrated, or the required resources and timelines are not justified. Whether "failure" is the right word is debatable. If we use it, the reality is that drug discovery is about managing failure. Within that, we need to decide whether to continue, modify or discontinue themes as needed, and feed the data and insights gained into subsequent target evaluation and compound design. The goal is not activity itself but converting it into business results. Going forward, we will assess scientific validity, competitive advantage, out-licensing potential, and resources and timelines. On that basis, we will be more selective about individual initiatives and prioritize the allocation of limited research resources more rigorously than before.

  • Q

    I appreciate business progress such as tegoprazan's growth. However, as a long-term shareholder, I have not seen adequate shareholder returns through share price appreciation or dividends. The company has said it would prioritize investment in the next phase of growth and consider shareholder returns afterward. Now that an earnings base is taking shape, isn't it time to start returning capital?

    A

    Thank you once again for your long-standing support. We take seriously the criticism that we have not delivered adequate results in terms of share price or shareholder returns. Share prices are set by the market, but we recognize that management decisions on earnings, growth strategy, capital allocation and disclosure affect market valuation. Shareholder returns are an important capital allocation option. We are not yet in a position to provide a specific timeline or numerical criteria, but we are not assuming indefinite deferral. We will decide holistically, weighing earnings stability, cash on hand, the balance with growth investment and share price levels, including both dividends and share buybacks. Partial or phased implementation is also under consideration. What matters is translating R&D investment into concrete results and higher corporate value. We will tighten investment discipline and communicate those results clearly.

  • Q

    You expect losses to continue on aggressive R&D spending. How much loss will you tolerate? How do you view the impact on current earnings and shareholder value?

    A

    R&D is necessary to generate future earnings, but increasing spending or simply starting projects is not the goal. For each theme, we assess validity, competitive advantage, out-licensing and commercialization potential, and required funding and timelines. On that basis, we decide whether to continue, prioritize, scale back or discontinue. We also set the total R&D budget and its allocation based on our earnings, cash on hand, future funding needs, financial soundness and the impact on shareholder value. We therefore have no intention of tolerating unlimited losses to continue investing. On the other hand, large swings in annual P&L driven by the timing of upfront and milestone payments are a weakness of our revenue structure. It would therefore be inappropriate to make investment or shareholder return decisions mechanically based solely on whether a single year is profitable. If investment results fall short, funding needs rise or the impact on financial flexibility grows, we will revisit theme priorities and investment levels, adjusting even mid-year.

  • Q

    Do you expect to sustain an operating profit in FY2027 on recurring royalty revenue alone?

    A

    Royalty revenue, centered on tegoprazan, is growing steadily, reaching JPY 2,055M in cumulative 3Q, +20.6% YoY. A simple calculation assuming 4Q tracks the first three quarters suggests JPY 2.5B may be within reach. However, this is still a projection and depends on the final outcome. Either way, our stable earnings base is steadily strengthening. In 2027, we expect this trend to continue if tegoprazan's performance in existing markets is complemented by geographic expansion and US approval and launch. Royalty revenue is precisely what is stable, and we expect it to grow. However, as I mentioned regarding our revenue structure, we are not yet at the point where royalties alone can sustain an operating profit. Stable revenue is very important, so we look to expand our royalty-driven earnings base. At the same time, we aim to steadily grow upfront and milestone revenue, and achieving both is our target revenue structure.

  • Q

    Can we assume there are no issues regarding the timing of US approval for tegoprazan?

    A

    We have nothing to add to the main presentation. In the US, the application was filed in January 2026. In October, sublicensee Sebela's announcement maintained the expected approval timing of January 2027. However, approval ultimately rests on the FDA's review and cannot be guaranteed. The review has not been interrupted so far, and no clear negative information has emerged to date. If any material fact requiring disclosure arises, we will disclose it appropriately in coordination with our partners.

Disclaimer

ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.

  • Purpose and Disclaimer Regarding Investment Decisions

    This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.

  • Information Sources, Accuracy, and Disclaimer of Warranty

    This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.

  • Limitation of Liability

    ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.

  • Potential Conflicts of Interest

    ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.

  • No Obligation to Change or Update Content

    The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.

  • Governing Language

    This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.

  • Copyright

    All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.

  • Use for Other Investment Products

    Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.